Related Experiment Video
Updated: Jan 14, 2026
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Loss of Mtarc1 Protects Against Steatotic Liver Disease in Mice
Xiaofei Yin1, Caroline Bickerton1, Bryan MacDonald1
1Cardiovascular Disease Initiative, Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA.
Background & Aims:
Metabolic dysfunction-associated steatotic liver disease (MASLD) spans from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH) and can progress to cirrhosis or hepatocellular carcinoma. Despite its prevalence, effective therapies are lacking. Recent genome-wide association studies identified a common missense variant (rs2642438) in the Mitochondrial Amidoxime Reducing Component 1 (MTARC1) gene that protects against liver cirrhosis without increasing cardiovascular disease risk. Biochemical and disease risk signatures associated with carriers of this missense variant also aligned with those of a known loss-of-function MTARC1 variant, suggesting mARC1 inhibition as a potential MASLD treatment.
Methods:
To validate mARC1 loss-of-function as protective against MASLD, we generated Mtarc1 knockout (KO) mice and placed them on a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD). Effects of Mtarc1 KO on obesity and type 2 diabetes were explored using a high-fat diet. Hepatocytes from Mtarc1 KO mice were isolated to explore the molecular mechanisms by which Mtarc1 KO impacts lipid metabolism.
Results:
Mtarc1 KO mice exhibited no vital growth or development defects. With a high-fat diet-induced obesity model, obese Mtarc1 KO mice exhibited reduced liver mass and lower cholesterol levels, with no effect on glucose homeostasis. In a CDAHFD-induced MASLD model, mARC1 deficiency significantly reduced liver steatosis, profibrosis, and inflammation. Untargeted metabolomics profiling further showed hepatic enrichment of phospholipids in Mtarc1 KO mice. Primary hepatocytes isolated from Mtarc1 KO mice exhibited reduced lipid droplet accumulation, decreased fatty acid uptake, and increased lipid secretion.
Conclusions:
These findings support mARC1 inhibition as a promising therapeutic strategy for MASLD/MASH.
Insights
Mitochondrial Amidoxime Reducing Component 1 (mARC1) inhibition shows promise for treating metabolic dysfunction-associated steatotic liver disease (MASLD). Studies in mice lacking mARC1 demonstrated reduced liver steatosis, inflammation, and fibrosis, supporting its therapeutic potential.
Area of Science:
- Hepatology and metabolic disease research.
- Genetics and molecular mechanisms of liver disease.
- Drug discovery and therapeutic strategies for MASLD.
Background:
- Metabolic dysfunction-associated steatotic liver disease (MASLD) encompasses a spectrum of liver conditions, from simple steatosis to severe stages like MASH and cirrhosis.
- Current therapeutic options for MASLD are limited, highlighting the urgent need for novel treatment strategies.
- Genetic studies identified a protective variant in the MTARC1 gene, suggesting mARC1 inhibition as a potential therapeutic target.
Purpose of the Study:
- To investigate the protective role of mARC1 loss-of-function against MASLD development.
- To explore the impact of mARC1 deficiency on obesity and type 2 diabetes.
- To elucidate the molecular mechanisms underlying mARC1's influence on hepatic lipid metabolism.
Main Methods:
- Generation of Mtarc1 knockout (KO) mice for studying mARC1 loss-of-function.
- Utilizing high-fat diet models to induce obesity and MASLD in wild-type and Mtarc1 KO mice.
- Isolation of primary hepatocytes from Mtarc1 KO mice to analyze lipid metabolism pathways.
Main Results:
- Mtarc1 KO mice showed no developmental defects and reduced liver mass/cholesterol in obesity models.
- mARC1 deficiency significantly attenuated liver steatosis, inflammation, and fibrosis in a MASLD model.
- Hepatocytes from Mtarc1 KO mice displayed altered lipid metabolism, including reduced lipid droplet accumulation and altered fatty acid uptake/secretion.
Conclusions:
- mARC1 loss-of-function demonstrates significant protective effects against MASLD pathogenesis.
- These findings strongly support mARC1 inhibition as a viable therapeutic strategy for MASLD and MASH.
- Further research into mARC1 inhibition could lead to novel treatments for these prevalent liver conditions.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...